RxDoctor Payments Data

Ashley van Hill

Family · Sioux Falls, SDNPI 1164815163

Payments from drug & device makers

$962in general payments, 2019–2025

Across 40 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$126
  • Geron Corporation$115
  • Legend Biotech USA Inc.$86
  • AbbVie$84
  • Novartis$79
  • Sanofi$72
  • plus $400 from 12 others

What the payments were for

  • Food & beverage$962100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$962 in reported general payments places this provider in the 75th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$33,292
Medicare patients
236
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide258$4,394,865
JakafiRuxolitinib Phosphate55$1,002,368
PomalystPomalidomide38$753,877
VenclextaVenetoclax80$557,380
BrukinsaZanubrutinib33$475,548
IclusigPonatinib Hcl17$431,016
ImbruvicaIbrutinib14$289,036
ScemblixAsciminib Hydrochloride13$274,270
SprycelDasatinib27$256,604
Lenalidomide17$251,332
RezurockBelumosudil Mesylate11$197,334
CalquenceAcalabrutinib Maleate14$195,690
DopteletAvatrombopag Maleate16$73,309
EliquisApixaban44$28,285
Atovaquone15$10,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$126$4,394,865258 claims
AbbVieVenclexta$84$557,38080 claims
Beigene USA, Inc.Brukinsa$37$475,54833 claims
NovartisScemblix$79$274,27013 claims
AstraZenecaCalquence$27$195,69014 claims
Johnson & JohnsonXarelto$50$6,78312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family providers in South Dakota.

Other family in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →